Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection
New England Journal of Medicine · 25.06.2026 · 394 (24) · 2395-2406
DOI: 10.1056/nejmoa2515131 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 25.06.2026. Verfasst von Jinlin Hou und 48 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, State Key Laboratory of Multi-organ Injury Prevention and Treatment…. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis B virus, Hepatitis B, Chronic, Oligonucleotides, Antisense. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: GlaxoSmithKline, GSK.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, State Key Laboratory of Multi-organ Injury Prevention and Treatment, Key Laboratory of Infectious Diseases Research in South China, Minis…
- Division of Gastroenterology and Hepatology, National University Health System, Singapore.
- Liver Unit, Hospital Universitario Vall d'Hebron, Centro de Investigación Biomédica en Red Enfermadades Hepáticas y Digestivas del Instituto Carlos III, Barcelona.
- Department of Medicine, School of Clinical Medicine and State Key Laboratory of Liver Research, Queen Mary Hospital, University of Hong Kong, Hong Kong.
- Liver Transplant Unit, University of Auckland, Auckland, New Zealand.
- Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan.
ORCID-Profile: Tarik Asselah, Xieer Liang
Förderung
- GlaxoSmithKline
- GSK
Zitieren
APA
Hou, J., Lim, S. G., Buti, M., Yuen, M. F., Gane, E., Lampertico, P., Terrault, N., Nguyen, H., Yim, H. J., Xie, Q., Lin, J., Qiu, Y., Jeng, W. J., Heo, J., Peng, C. Y., Chen, C. H., Chuang, W. L., Xie, Y., Hlebowicz, M., …, & B-Well Study Group (2026). Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection. New England Journal of Medicine, 394(24), 2395-2406. https://doi.org/10.1056/nejmoa2515131
Vancouver
Hou J, Lim SG, Buti M, Yuen MF, Gane E, Lampertico P, et al. Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection. New England Journal of Medicine. 2026;394(24):2395-2406. doi:10.1056/nejmoa2515131
BibTeX
@article{Hou2026,
author = {Hou, Jinlin and Lim, Seng-Gee and Buti, Maria and Yuen, Man-Fung and Gane, Edward and Lampertico, Pietro and Terrault, Norah and Nguyen, Huy and Yim, Hyung Joon and Xie, Qing and Lin, Jianmei and Qiu, Yunqing and Jeng, Wen-Juei and Heo, Jeong and Peng, Cheng-Yuan and Chen, Chien-Hung and Chuang, Wan-Long and Xie, Yao and Hlebowicz, Maria and Idriz, Nevin and Mehta, Rajiv and Agarwal, Kosh and Gomes da Silva, Monica M and Franca, Alex and Cernat, Roxana and Leerapun, Apinya and Coffin, Carla S and Gadano, Adrian and Andreone, Pietro and Fujiyama, Shigetoshi and Sevastianos, Vasileios and Suzuki, Yuichiro and Ratziu, Vlad and Riachi, Ghassan and Stocker, Hartmut and Lim, Tien Huey and Asselah, Tarik and Tanaka, Yasuhito and Holmes, Jacinta and Liang, Xieer and Cremer, Jennifer and Lukić, Tamara and Plein, Helene and Quinn, Geoff and Tao, Yu and Paff, Melanie and Theodore, Dickens and Elston, Robert and B-Well Study Group, B-Well Study Group},
title = {Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection},
journal = {New England Journal of Medicine},
year = {2026},
volume = {394},
number = {24},
pages = {2395--2406},
doi = {10.1056/nejmoa2515131}
}
EUVIMED